September 16, 2019

Application Period Now Open for Boehringer Ingelheim Research Awards on Porcine Respiratory Diseases

Program funds field-applicable research into critical swine diseases

DULUTH, Georgia (Sept. 16, 2019) — Practicing veterinarians, researchers and academics may now apply for one of three $35,000 awards for research related to infectious respiratory disease in pigs.

Boehringer Ingelheim sponsors the Awards for Advancing Research in Respiratory Disease (AWARRD). The program has provided $1.3 million since 2002 for research into some of the industry’s most pressing questions about the diagnosis, control and management of porcine respiratory infectious diseases.

The deadline is Jan. 15, 2020, to apply for awards. The Respiratory Disease Research Board, which consists of seven independent swine veterinarians and researchers, will review applications. 

Proposals may relate to:

  • Porcine circovirus Type 2 (PCV2)
  • Mycoplasma hyopneumoniae (Mhp)
  • Influenza A virus in swine (IAV-S)
  • Porcine reproductive and respiratory syndrome (PRRS)

“Research is the driving force behind the development of innovative, field-applicable solutions to the problems facing swine producers and veterinarians,” said Reid Philips, DVM, PRRS technical manager, Boehringer Ingelheim. “Throughout the history of the AWARRD program, I have been inspired by the researchers who have participated and the collaborative nature of their work. The knowledge that has been gained with the help of funding from this program has truly shaped the course of pork production, and I’m excited to see where this year’s recipients take us next.”

Visit www.swineresearchawards.com to learn more.

 

***

About Boehringer Ingelheim Animal Health USA Inc. 
 
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
 
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
 
About Boehringer Ingelheim
 
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
 
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
 
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Media Contacts
Keith Grauman
PR Director 
broadhead
(612) 659-4420
kgrauman@broadheadco.com

Mark Bixler
Head of External Communications and Content Strategy
Boehringer Ingelheim Animal Health – U.S.
(678) 209-3077
mark.bixler@boehringer-ingelheim.com 

©2019 Boehringer Ingelheim Animal Health USA Inc. US-POR-0088-2019